American National Bank & Trust Sells 1,906 Shares of Amgen Inc. $AMGN

American National Bank & Trust reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.4% during the 3rd quarter, HoldingsChannel reports. The firm owned 33,093 shares of the medical research company’s stock after selling 1,906 shares during the quarter. Amgen comprises about 1.2% of American National Bank & Trust’s investment portfolio, making the stock its 26th biggest position. American National Bank & Trust’s holdings in Amgen were worth $13,949,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Baird Financial Group Inc. increased its stake in Amgen by 1.6% in the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after acquiring an additional 5,496 shares during the period. MW Advisory LLC acquired a new stake in Amgen during the second quarter valued at approximately $1,054,000. Integrated Advisors Network LLC boosted its holdings in Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock valued at $6,664,000 after purchasing an additional 6,356 shares in the last quarter. KBC Group NV grew its stake in shares of Amgen by 51.7% in the 2nd quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock valued at $138,574,000 after purchasing an additional 130,497 shares during the period. Finally, Nilsine Partners LLC bought a new stake in shares of Amgen in the 2nd quarter valued at approximately $3,329,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported that its AMG 513 obesity-drug study completed Phase 1. The milestone provides an additional potential growth opportunity in the competitive weight-loss market, although clinical efficacy and safety data remain important next steps. Amgen AMG 513 obesity trial article
• Positive Sentiment: Scotiabank raised its price target for Amgen from $450 to $500, signaling greater confidence in the company’s upside potential and supporting sentiment around the stock. Scotiabank raises Amgen price target
• Neutral Sentiment: Truist raised its target from $362 to $380 but maintained a Hold rating. The revised target remains below the recent trading level, limiting the bullish impact of the increase.
• Neutral Sentiment: Cantor Fitzgerald reiterated a Neutral rating, while another report cited a $400 target. These views suggest analysts see limited near-term upside after Amgen’s strong run. Cantor Fitzgerald Amgen rating
• Neutral Sentiment: Amgen has become a heavily watched or “trending” stock on Zacks, which may increase trading attention but does not represent a fundamental change in the company’s outlook. Zacks Amgen trending stock article
• Negative Sentiment: Morgan Stanley lowered its target from $362 to $359 and retained an Equal Weight rating. The target implies substantial downside from current levels, reinforcing concerns that expectations and valuation may be elevated. Morgan Stanley Amgen price target report

Amgen Price Performance

Shares of Amgen stock traded up $10.57 during trading on Wednesday, reaching $413.17. The company’s stock had a trading volume of 939,280 shares, compared to its average volume of 2,751,854. The stock has a 50-day moving average price of $411.44 and a two-hundred day moving average price of $371.01. The stock has a market capitalization of $223.37 billion, a P/E ratio of 25.68, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a one year low of $288.00 and a one year high of $447.03.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Analyst Ratings Changes

Several research firms recently commented on AMGN. Truist Financial raised their target price on Amgen from $362.00 to $380.00 and gave the stock a “hold” rating in a research report on Wednesday. Wells Fargo & Company increased their price objective on Amgen from $400.00 to $435.00 and gave the stock an “equal weight” rating in a research note on Friday, September 4th. Cantor Fitzgerald reissued a “neutral” rating on shares of Amgen in a report on Monday. HSBC downgraded shares of Amgen from a “buy” rating to a “hold” rating and reduced their target price for the company from $445.00 to $425.00 in a research note on Thursday, September 10th. Finally, BMO Capital Markets lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $450.00 target price on the stock. in a report on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $385.79.

Insider Buying and Selling

In related news, SVP Nancy Grygiel sold 2,970 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.